Rockville-based Human Genome Sciences Inc., which rejected a $13-per-share takeover offer from GlaxoSmithKline PLC as too low, has accepted a $14.25 per share offer from its lupus drug development partner. The handshake brings to a close a monthslong, sometimes tense struggle for control of the company.
Glaxo announced Monday that Human Genome Sciences (NASDAQ: HGSI) had agreed to its offer to acquire the company in a $3.6 billion squirt transaction that values Human Genome at $3 billion net of cash and debt.
{iframe}http://www.bizjournals.com/washington/news/2012/07/16/glaxosmithkline-to-buy-human-genome.html?ana=e_du_pap&s=article_du&ed=2012-07-16{/iframe}